Evidence map›Paper›PMID 38067464›Full record

ReviewMolecules (Basel, Switzerland)2023

Sonosensitive Cavitation Nuclei-A Customisable Platform Technology for Enhanced Therapeutic Delivery.

Brian Lyons, Joel P R Balkaran, Darcy Dunn-Lawless, Veronica Lucian, Sara B Keller, Colm S O'Reilly, Luna Hu, Jeffrey Rubasingham, Malavika Nair, Robert Carlisle and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Harnessing Ultrasonic Technologies to TreatMolecules (Basel, Switzerland) · 2025
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Brian LyonsInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford OX1 3PJ, UK.ORCID 0000-0002-2779-8732
Joel P R BalkaranInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford OX1 3PJ, UK.ORCID 0000-0001-7797-6798
Darcy Dunn-LawlessInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford OX1 3PJ, UK.ORCID 0000-0002-6937-0427
Veronica LucianInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford OX1 3PJ, UK.ORCID 0000-0002-2242-5494
Sara B KellerInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford OX1 3PJ, UK.ORCID 0000-0001-5087-4775
Colm S O'ReillyBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford OX1 3PJ, UK.ORCID 0000-0001-8316-0138
Luna HuInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford OX1 3PJ, UK.
Jeffrey RubasinghamInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford OX1 3PJ, UK.
Malavika NairInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford OX1 3PJ, UK.ORCID 0000-0002-5229-8991
Robert CarlisleInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford OX1 3PJ, UK.
Eleanor StrideInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford OX1 3PJ, UK.ORCID 0000-0003-3371-5929
Michael GrayInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford OX1 3PJ, UK.ORCID 0000-0002-3245-3296
Constantin CoussiosInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford OX1 3PJ, UK.

Funding

The authors gratefully acknowledge financial support from the generous benefaction of Mr Donald Porteus (BL, JB, RC, MG and CC research support) Other
6 · The paper itself

Abstract

Ultrasound-mediated cavitation shows great promise for improving targeted drug delivery across a range of clinical applications. Cavitation nuclei-sound-sensitive constructs that enhance cavitation activity at lower pressures-have become a powerful adjuvant to ultrasound-based treatments, and more recently emerged as a drug delivery vehicle in their own right. The unique combination of physical, biological, and chemical effects that occur around these structures, as well as their varied compositions and morphologies, make cavitation nuclei an attractive platform for creating delivery systems tuned to particular therapeutics. In this review, we describe the structure and function of cavitation nuclei, approaches to their functionalization and customization, various clinical applications, progress toward real-world translation, and future directions for the field.

Indexed as

Drug Delivery SystemsMicrobubblesUltrasonographycavitationcavitation nucleidrug deliverynanoparticlessonosensitiveultrasound

Identifiers

PMID38067464
PMCPMC10708135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.